Aim: Left ventricular (LV) thrombus is one of the risk factors for systemic thromboembolism. The aims of this study were to compare the long-term clinical outcomes of LV thrombus using current therapeutics, anticoagulation, operative treatment, and antiplatelet agents and to identify independent predictors of systemic thromboembolism. Methods: We screened 86,374 patients for intracardiac thrombus in the electronic medical records and imaging databases. Records of 62 patients with LV thrombus, diagnosed between May 2003 to November 2011, were comprehensively reviewed regarding baseline characteristics, imaging data and thrombus outcomes, thromboembolic events and treatment complications by treatment group. Results: The majority (80.6%) had ischemic etiology. Systemic thromboembolism developed in 18 patients; 8 (45%) were post-treatment thromboembolisms while 10 events occurred before treatment began. No post-treatment thromboembolism occurred in the operative treatment group; in contrast, 7 post-treatment thromboembolisms occurred in anticoagulation group (17%) (Log rank p = 0.175). Independent predictors of post-treatment thromboembolism were dilated cardiomyopathy (HR 61.30, p=0.001), previous cerebrovascular events (HR 7.06, p= 0.042) , female gender (HR 7.11, p = 0.031), and echocardiographic left ventricular end-diastolic diameter (HR 1.15, p= 0.047) . Conclusions: In this study, the rate of post-treatment thromboembolism was not significantly different among the treatment groups; however, operative treatment tended towards less post-treatment thromboembolism than other treatment groups. , 2013; 20:73-93. 
Introduction
Left ventricular (LV) thrombus formation is a frequent complication of ischemic heart disease, particularly in acute myocardial infarction (MI), even after successful revascularization 1) . At least 5% of patients develop LV thrombus after acute MI 2) . Various other conditions, including idiopathic dilated cardiomyopathy (DCMP), stress-induced cardiomyopathy and valvular heart disease-induced severe LV dysfunction, are known risk factors for LV thrombus formation 3, 4) .
The clinical relevance of LV thrombus is the association with increased risk of systemic arterial thromboembolism [5] [6] [7] . It is known that anticoagulation therapy with warfarin reduces both the risk of LV thrombus formation and subsequent thromboembo-resonance imaging (MRI) or coronary computed tomographic (CT) angiography were included as study subjects. From May 2003 to November 2011, we performed 75,936 two-dimensional transthoracic echocardiographies (TTEs), 1,100 cardiac MRIs and 9,338 coronary CT angiographies (CTAs). The respective imaging databases were screened for intra-cardiac thrombus; 69 patients were found with LV thrombus. After 7 of these patients, whose transesophageal echocardiography (TEE) confirmed no intra-cardiac thrombus, were excluded from this analysis, 62 patients remained as study patients (Fig. 1) .
A comprehensive review of each patient's clinical data was performed using the electronic medical record system to identify baseline characteristics and medications at the time of LV thrombus diagnosis. Medical records were also evaluated for echocardiographic parameters, morphology of the LV thrombus in three imaging modalities, treatment of the LV thrombus, initial anticoagulation, details of the operative procedure, events of systemic thromboembolism, cardiac or all-cause mortality and complications of treatment including major or minor bleeding.
Decisions regarding the treatment strategy for LV thrombus were made by the patient's primary physi-lism, but increases the risk of bleeding [7] [8] [9] . Current ACC/AHA guidelines recommend anticoagulation with warfarin for patients with LV thrombus or cardioembolic stroke (class Ⅰ, level of evidence: b) 10) ; however, chronic anticoagulation has inevitable bleeding complications.
Moreover, the long-term consequences and frequency of systemic thromboembolism after conventional anticoagulation for LV thrombus have not been sufficiently investigated. Evidence of the superiority of conventional anticoagulation relative to surgical removal or antiplatelet agents is scarce, as are studies of independent predictors of systemic thromboembolism. The aims of this study were to investigate long-term clinical outcomes for LV thrombus, including the rate of systemic thromboembolism and complications of current therapeutics (conventional anticoagulation, operative treatment, antiplatelet agents) and to indentify independent predictors of systemic thromboembolism.
Materials and Methods

Patient Population and Data Collection
All patients with LV thrombus, diagnosed by two-dimensional echocardiography, cardiac magnetic early gadolinium enhancement and late gadolinium enhancement imaging. All subjects underwent coronary CTA with retrospective ECG gating on a 64 channel Multi-Detector CT scanner (Brilliance iCT; Philips Medical System, Boston, USA). Detailed imaging protocol of cardiac MRI and coronary CTA is presented in Supplementary Materials.
Definitions and Outcome Analysis
The conventional anticoagulation group was defined as patients who were prescribed warfarin, regardless of antiplatelet agent use. If the patient had undergone surgical removal of LV thrombus, the patient was classified into the operative treatment group, regardless of medication status. The antiplatelet agent group included patients who had received neither warfarin nor operative treatment for LV thrombus and who were taking one or more antiplatelet agents. In our study, many systemic thromboembolisms had occurred before treatment of LV thrombus began. Thus, we separated thromboembolic events as pre-treatment or post-treatment events. Embolic events that developed before the initiation of LV thrombus treatment were defined as pre-treatment. In contrast, embolic events that developed after the initiation of anticoagulation, antiplatelet agents or operative treatment were defined as post-treatment thromboembolism.
The primary outcome of the main analysis was the rate of post-treatment thromboembolism that included embolic cerebral infarction, transient ischemic attack and peripheral embolism. For cerebral infarction, the events were classified as embolic if the criteria, previously reported by Hart et al. 12) , were met. Transient ischemic attack was defined as any focal neurologic deficit of sudden onset that lasted ＜30 min and lacked abnormal findings on brain MRI. Peripheral thromboembolism was defined as a combination of signs and symptoms of end organ ischemic damage that was confirmed by conventional angiography or CTA.
The cause of death was classified as cardiac or non-cardiac, defined according to Academic Research Consortium definitions 13) . Bleeding events were defined according to the Thrombolysis in Myocardial Infarction (TIMI) criteria 14) . Major bleeding was defined as any intracranial hemorrhage, more than a 5 g/dL decrease in the hemoglobin concentration or more than a 15% absolute decrease in the hematocrit.
Outcomes related to thrombus morphology and changes of the maximum size were also evaluated. Follow-up echocardiography was performed in 48 patients (77.42%). Resolution of LV thrombus and the follow-cian. All patients who were anticoagulated with warfarin were evaluated by the Anticoagulation Service in our institution at least 1 or 2 times a month to maintain a stable prothrombin time (PT) international normalized ratio (INR) value between 2 to 3. If the patients were treated with an antiplatelet agent only, the reasons for no anticoagulation were determined by medical record review and consultation with the patient's primary physician. An attempt was made to contact and interview, via telephone, all patients who were lost to follow-up. Except for 9 patients, including 4 deceased patients and 5 follow-up losses, all patients are currently being followed. This study was approved by the institutional review board.
Imaging Modalities Two-Dimensional Echocardiography
Two-dimensional echocardiographic examinations were performed using three different commercially available systems (Vivid E9, GE Healthcare, Wilmington, MA, USA; Sonos 7500, Philips Medical Systems, Einthoven, The Netherlands; Sequoia C512, Siemens Medical Solutions, Erlangen, Germany) and standard techniques in accordance with the guidelines of the American Society of Echocardiography 11) . LV thrombus was defined as an echo-dense mass within the ventricular cavity with 1) a marked delineation toward the lumen and 2) a structural texture different from the myocardium and that 3) could be separated from the underlying endocardium by an endocardial lining; 4) was visible throughout the entire cardiac cycle; and 5) could be demonstrated in at least two different views as previously described 8) . Any suspected diagnosis of LV thrombus with TTE was confirmed by TEE using the same equipment (Vivid E9; GE Healthcare). Thrombus shape was classified as pedunculated (with demonstration of pendulations apart from those mediated by myocardial contraction) or sessile; thrombus mobility was defined as mobile or mural. A mobile thrombus, including pedunculated or multiple thrombi, was categorized as a high-risk LV thrombus. The left ventricular ejection fraction and left atrial size were calculated by volumetric methods, which were measured in both apical 4-chamber and 2-chamber views. Every echocardiographic finding was confirmed at the time of examination by the staff of our institution, who specialize in cardiovascular imaging.
Cardiac MRI and Coronary CT Angiography
Cardiac MRI was performed with a 1.5 Tesla MR system (Philips Medical System). The imaging protocol included cine-MRI, T2-weighted imaging, up size of the thrombus were abstracted from the database. Thrombus resolution was strictly defined as complete resolution, that is, no evidence of LV thrombus on follow-up echocardiography. Width and thickness of the thrombus were recorded; maximum thrombus size was defined as the greatest value among all widths and thicknesses.
Statistical Analysis
Categorical variables are presented as numbers and relative frequencies (percentages) and were compared using the χ 2 test or Fisher's exact test, as appropriate. Normally distributed continuous variables are expressed as the means and standard deviations, and between-group differences were analyzed using the independent sample t -test or the Mann-Whitney U test as appropriate. The three treatment modalities were compared using the Kruskal-Wallis test for continuous variables and χ 2 test for categorical variables. Pairwise comparisons between two groups were performed as post-hoc analysis using the Bonferroni corrected p value. The change in LV thrombus size, before and after treatment, was evaluated with the Wilcoxon signed rank sum test. Kaplan-Meier analysis was used to calculate the cumulative incidence of the primary outcomes (post-treatment thromboembolism) and the log rank test or Breslow test was used to compare the differences in event-free survival among the groups, as appropriate.
A Cox proportional hazard regression model was used to evaluate the adjusted hazard ratio (HR) of each clinical variable and to identify independent predictors of pre-treatment or post-treatment systemic thromboembolism. Variables were included as covariates in multivariate analyses if they were distributed differently among the treatment groups, were associated with the primary outcome in univariate analyses or were generally accepted as potential confounders. The adjusted covariates are shown in Supplementary  Table 1 . Since there were differences in important baseline characteristics, such as the proportion of mobile or multiple thrombi and the maximum thrombus size among the three treatment groups, particularly between the anticoagulation group and antiplatelet agent group, we performed two 1:1 matched analyses without replacement (one compared the anticoagulation and operative treatment groups, the other compared the anticoagulation and antiplatelet agent groups) using a propensity score. The log-odds of the probability that a patient was treated with surgical removal or antiplatelet agents was modeled as a function of the confounders. A caliper width of 0.6 SDs was used because this value has been shown to elimi- Others included coronary vasodilators (nicorandil) or metabolic agents (vastinan). Abbreviations: AS, aortic stenosis; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CMP, cardiomyopathy; CRF, chronic renal failure; CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; HCMP, hypertrophic cardiomyopathy; LA, left atrium; LAVI, left atrium volume index; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LVEF, left ventricular ejection fraction; RWMA, regional wall motion abnormality; STEMI, ST segment elevation myocardial infarction.
or antithrombin deficiency or antiphospholipid antibody syndrome. In addition, no patient had both LV thrombus and ventricular non-compaction, which has been associated with systemic thromboembolism 16) .
Thrombus Characteristics and Echocardiographic Parameters
All of the LV thrombi were located in the cardiac apex and most had mural attachment and sessile morphology (53 patients, 85.5%) ( Table 1) . High-risk thrombi (mobile thrombi including pedunculated or multiple thrombi) were more frequent in patients with thromboembolism (9.1% vs. 27.8%, p=0.058). Patients with or without thromboembolism had similar echocardiographic parameters, excepting that the LA size was larger in patients with thromboembolism ( Table  1) . Using the aforementioned analysis, several variables, including thrombus mobility, maximum thrombus size, echocardiographic parameters and medication history, were selected as covariates for multivariate analysis to elucidate independent predictors of systemic thromboembolism ( Supplementary Table 1 ). nate almost 90% of the bias in the observed confounders 15) . All probability values were two-sided and p-values ＜0.05 were considered statistically significant. In case of Bonferroni correction, p-values ＜0.017 were considered statistically significant. The statistical package SPSS, version 18.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism, version 5 (GraphPad Software Inc., La Jolla, CA, USA) were used for statistical analyses.
Results
Patient Population and Baseline Characteristics
Among 86,374 patients who underwent twodimensional echocardiography, cardiac MRI, or coronary CTA from May 2003 to November 2011, 62 patients had documented LV thrombus ( Fig. 1) . Mean age was 63.61±13.94 years, the majority were male (80.6%) and had ischemic heart disease (80.6%) including acute MI ( Table 1) . Twenty-one patients (33.9%) were admitted due to acute ST segment elevation MI (STEMI) that was treated with primary percutaneous coronary intervention within 90 minutes of door-to-balloon time (19 patients, 90.5%) or thrombolysis within 30 minutes of door-to-needle time (2 patients, 9.5%). All patients with STEMI had anterior wall myocardial infarction.
Eighteen of 62 patients (29%) developed systemic thromboembolism, with pre-treatment and post-treatment thromboembolism combined. There were no significant differences in baseline characteristics or medication history between patients with or without thromboembolism except for warfarin. Most patients (72.6%) were taking low-dose acetylsalicylic acid (100 mg/day) and 35.5% of patients were taking clopidogrel.
None of the study patients had hypo-or hyperthyroidism or a medical or familial history of congenital thrombophilic disorders, for example, protein C, S In the anticoagulation group, adequate ranges of PT INR were maintained and the mean PT INR value was 2.75±0.43 during the treatment period (median 327 days). In 18 (42.9%) patients, anticoagulation was discontinued due to complete resolution of thrombus, based on follow-up echocardiography, (11 patients, 61.1%), bleeding (major bleeding: 1 patients, 11.1%; minor bleeding: 3 patients, 16.7%), death (2 patients including 1 death due to major bleeding, 11.1%) and refusal by the patient (1 patient, 5.6%). None of the 11 patients who discontinued warfarin after TEE showed complete resolution of LV thrombus had post-treatment thromboembolism. Follow-up TEE did not detect recurrence of LV thrombus when performed in 4 patients after resolution of the thrombus (median duration of follow-up echocardiography: 456 days (IQR 193.75-888.50 days).
Diagnostic Modalities
TTE was performed in 61 of the 62 study patients; however, LV thrombus was diagnosed only in 48 patients (78.7%) ( Table 2 ). In the remaining 13 patients, LV thrombus was recognized by cardiac MRI or coronary CTA, as shown in Supplementary Fig. 1 .
Treatment Groups for the LV Thrombus
Each patient was treated for LV thrombus with one of three treatment options according to the primary physician's decision; 42 (67.7%) were treated with conventional anticoagulation, 8 (12.9%) with operative treatment and 12 (19.4%) only with antiplatelet agents ( Table 3 ). There were no significant differences in baseline characteristics except for 1 patient with severe aortic valve stenosis in the operative treatment group. platelet agent group ( Table 4 and Fig. 2A) . Moreover, follow-up echocardiography showed complete resolution of thrombus in all patients in the operative treatment group (Fig. 2B) . In the antiplatelet agent group, follow-up size of the thrombus was not significantly different from the initial size ( Fig. 2A) .
Clinical Outcomes
Ten (55.0%) of the 18 thromboembolism events occurred before the treatment began (pre-treatment thromboembolism). Post-treatment thromboembolism developed in 17.1% of the anticoagulation group, 0% of the operative treatment group and 8.3% of the antiplatelet agent group, without statistically significant differences ( Table 4) . Thromboembolism-free survival of the treatment groups, depicted in Fig. 3A , showed a tendency towards longer survival in the operative and antiplatelet agent groups than in the anticoagulation group, which was not significantly different. During the median follow-up of 24 months, All but one patient in the operative treatment group were diagnosed with 3-vessel disease, which required coronary artery bypass grafting (CABG). One patient had been diagnosed with severe aortic stenosis due to a bicuspid aortic valve (Supplementary Table 2 ). The median interval from thrombus detection to operation was 5 days ( Table 3 ).
The 12 patients that were treated only with antiplatelet agents had at least one reason that precluded anticoagulation (Supplementary Fig. 2) . The most frequent reason for preclusion was a high risk for bleeding (7 patients).
Thrombus Outcomes
The frequency of high-risk thrombi did not differ among the treatment groups; however, the maximum thrombus size was significantly smaller in the antiplatelet agent group ( Table 4 ). The relative size decrease was significantly greater in the anticoagulation and operative treatment groups than in the anti- lation group there were 2 cardiac deaths (one cardiogenic shock due to non-ST segment elevation myocardial infarction and one sudden cardiac death due to ventricular tachycardia) and one death due to massive gastrointestinal bleeding. One patient in the antiplatelet agent group died of septic shock.
Supplementary
Clinical Outcomes in Propensity Score Matched Groups
Post-treatment thromboembolism showed a tendency towards a lower rate in the operative and antiplatelet agent groups than in the anticoagulation group (Fig. 3A) ; however, the frequency of high-risk thrombi and thrombus maximum size were lower in the antiplatelet agent group. In addition, the treatment groups differed in baseline characteristics including medications and thrombus profiles (Table 3 and 4) . Because of such differences, we performed propensity score matching, which yielded 8 pairs for each comparison, anticoagulation versus operative treatment and anticoagulation versus antiplatelet agents. Matching produced more balanced groups, particularly with respect to medications and thrombus profiles (Supplementary Table 3 and 4).
In this comparison of the anticoagulation versus operative treatment groups, two post-treatment thromboembolism events occurred, both in the anticoagulation group ( Supplementary Table 3 ). In addition, survival curves showed more prominent differences in the event-free survival (Fig. 3B ) compared with that of unmatched analysis (Fig. 3A) .
In contrast, one patient in each group suffered post-treatment thromboembolism in the matched pairs of the anticoagulation and antiplatelet agent groups (Supplementary Table 4 ). The tendency towards lower post-treatment thromboembolism in the antiplatelet agent group in the survival curve, which was found in the unmatched analysis (Fig. 3A) , disappeared in the propensity score-matched analysis (Fig. 3C) .
Clinical Outcomes According to the Underlying Heart Condition
The treatment groups were inhomogeneous with respect to the underlying heart condition, and ischemic etiology was found in 32 (76.2%), 7 (87.5%) and 11 (91.7%) of patients treated with anticoagulation, operative treatment and antiplatelet therapy, respectively ( Table 3) . Among patients with non-ischemic etiology, 10 patients were treated with anticoagulation, 1 patient with operation, and 1 patient with antiplatelet therapy. Among all study subjects, only 5 (8.1%) patients had DCMP; all were treated with anticoagulation. Therefore, we performed further no post-treatment thromboembolism event occurred in the operative treatment group; in contrast, such events occurred in the anticoagulation group and antiplatelet agent group.
Major and minor bleeding events developed more frequently in the anticoagulation group than in the operative treatment group; however, one patient in the operative treatment group developed postoperative bleeding from a right internal thoracic artery harvesting site ( Table 4) . Notably, the two major bleeding events in the anticoagulation group consisted of intracranial bleeding that resulted in permanent neurologic sequelae and massive gastrointestinal tract bleeding that resulted in death. All three minor bleeding events occurred in the anticoagulation group. All the bleeding events precluded further maintenance of anticoagulation.
There were 4 deaths ( Table 4 ). In the anticoagu- Supplementary Fig. 2 . Reasons for not using Anticoagulation in the Antiplatelet Agent Group.
Twelve patients were treated with one or more antiplatelet agents only. The reason that precluded anticoagulation with warfarin is depicted. Seven patients were considered at high risk for bleeding for the following reasons: recurrent gastrointestinal tract bleeding due to benign peptic ulcer disease or inflammatory bowel disease, 4 patients; receiving intraocular treatment for medically intractable glaucoma, 1 patient and liver cirrhosis Child class B to C with PT prolongation, 2 patients. Three patients, who had advanced dementia and lacked care-givers, were considered to be unable to keep comply with the details of warfarin anticoagulation and required regular follow-up.
yses (OR, 0.05; 95% CI, 0.00-1227.12; p = 0.977).
Independent Predictors of Thromboembolism
Using a Cox proportional hazard regression model with the aforementioned multiple covariates (Supplementary Table 1) , independent predictors of pre-treatment thromboembolism were cardiac arrest and mobile or multiple thrombi. Independent predictors of post-treatment thromboembolism were female gender, a previous cerebrovascular event, DCMP and large left ventricular end-diastolic diameter (LVEDD) ( Table 5 ). Treatment modalities (anticoagulation, operative treatment, or antiplatelet agents) were not independent predictors of systemic thromboembolism.
analyses according to the underlying etiology, ischemic versus non-ischemic and DCMP versus no DCMP (Supplementary Table 5 ).
Post-treatment thromboembolism developed in 2 patients (40%) with DCMP. In univariate analysis, DCMP was associated with a 5.6-fold increased risk for post-treatment thromboembolism (OR, 5.67; 95% CI 0.78-41.01; p = 0.059). After adjustment for potential confounders, DCMP remained a strong and significant independent predictor of post-treatment thromboembolism ( Table 5 ). In contrast, ischemic cardiomyopathy was not associated with post-treatment thromboembolism in univariate (OR, 0.68; 95% CI, 0.12-3.89; p = 0.665) or in multivariate anal- Interval to follow-up echocardiography, data are expressed as median and interquatile range. Bleeding events were defined according to the Thrombolysis in Myocardial Infarction (TIMI) criteria. Major bleeding was defined as any intracranial hemorrhage, more than a 5 g/dL decrease in the hemoglobin concentration or more than a 15% absolute decrease in the hematocrit. One patient in the operative treatment group developed postoperative bleeding from the right internal thoracic artery harvest site. The patient was successfully treated with re-do sternotomy and bleeding control. ＃ These two major bleeding events included one death due to massive hematemesis and subsequent hypovolemic shock. Abbreviations: Echo, echocardiography; IQR interquatile range; TIA, transient ischemic attack.
with post-treatment thromboembolism, with marginal statistical significance (Supplementary Table 6) ; however, we could not build a model for multivariate analysis in this subgroup due its small size.
Univariate analysis of the subgroup with nonischemic etiology (n=12) without indications for open heart surgery, found that LVEDD and the proportion of mobile or multiple thrombi were greater in those A) Changes of LV thrombus size (mm). B) Thrombus resolution rate based on follow-up echocardiography. The resolution rate was significantly different among the three groups. The resolution rate was significantly higher in the operative treatment group than in the antiplatelet agent group (100.0% vs. 25.0%, Bonferroni corrected p = 0.007). However, there was no significant difference in the relative size change and resolution rate between anticoagulation group and operative treatment group in the post-hoc analysis. The results of Wilcoxon signed rank sum test for the analyses of the change of LV thrombus size before and after the treatment are presented. Post-hoc analyses with Bonferroni corrected p value are also presented. Asterisk denotes a statistically significant p value.
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The operative treatment group had no post-treatment thromboembolisms and the highest resolution rate and decrease of LV thrombus size. The conventional anticoagulation group had the highest rate of post-treatment embolism (7 of 8 events, 87.5% occurred in this group), despite a larger decrease in thrombus size than in the antiplatelet agent group. Notably, post-treatment thromboembolism even occurred during adequate maintenance of the target PT INR.
Discussion
The current study measured the long-term outcomes of treatment strategies during a median followup of 24 months. The overall risk of systemic thromboembolism during 2 years was 29.0%. Over one-half of the systemic thromboembolisms (55.0%) occurred before the detection of LV thrombus (pre-treatment thromboembolisms). The rate of post-treatment thromboembolism was not significantly different among the three treatment groups. studies. The reported resolution rate of thrombus with anticoagulation is also variable, ranging from 48% at 6 months follow-up to 65-85% at 24-month followup 9, 17, 20, 21) . Similarly, the resolution rate of the thrombus in our study was 65.6% in the anticoagulation group. The remaining chronic thrombus also confers a substantial risk of systemic thromboembolism 5, 19) . These prior studies support our findings that conventional anticoagulation is not able to eliminate the risk of systemic thromboembolism, even with adequate maintenance of anticoagulation, unless the LV thrombus has completely disappeared.
Outcomes of Operative Treatment
Even though we failed to detect a statistically significant difference in event-free survival between the anticoagulation and operative treatment groups, this tendency towards longer survival in the operative treatment group increased after imbalances in baseline covariates were corrected with propensity score matching. It is noteworthy that the clinical severity of the operative treatment group was greater than that of the other groups. Three of eight patients in the operative treatment group had undergone surgery with mechan-
Embolic Risk of Conventional Anticoagulation
Regarding the efficacy of anticoagulation, two previous meta-analyses found that the relative risk of embolism in anticoagulated patients with LV thrombus after myocardial infarction was 0.3 (95% CI 0.1-0.5) and 0.14 (95% CI 0.04-0.52) 7, 9) ; however, these studies only compared the efficacy of anticoagulation with that of no anticoagulation. Moreover, these metaanalyses did not evaluate dual antiplatelet agents (acetylsalicylic acid and clopidogrel), which are common current therapeutics for patients with acute myocardial infarction. Prior studies reported various rates of post-treatment thromboembolism (from 0% to 33.3%) even with adequate anticoagulation. The rate of post-treatment embolism of these studies is as follows: Nihoyannopoulos et al. 17 Bleeding events were defined according to the Thrombolysis in Myocardial Infarction (TIMI) criteria. Major bleeding was defined as any intracranial hemorrhage, more than a 5 g/dL decrease in the hemoglobin concentration or more than a 15% absolute decrease in the hematocrit. Abbreviations: CVA, cerebrovascular accident; echo, echocardiography. of intracranial hemorrhage by 2-5-fold 27, 28) . Furthermore, the known propensity of major bleeding to increase mortality is supported by several clinical trials, including the REPLACE-2 trial 29) and the TRI-TON-TIMI 38 trial 30) . The overall hazard ratio of bleeding, including major and minor bleeding, was 5.84 (95% CI 4.11-8.29) in the TRITON-TIMI 38 trial 30) . In our study, the risks of major bleeding and mortality associated with bleeding were considerable. Meticulous risk stratification regarding bleeding and systemic thromboembolism should be considered before starting anticoagulation.
Predictors of Embolism
To facilitate treatment that is more individualized than routine anticoagulation, it is important to establish selection criteria for patients at high-risk of systemic thromboembolism. Through Cox proportional hazard regression modeling, we found that mobile or multiple thrombi were independent predictors of pre-treatment thromboembolism, as previously reported 1, 5, 6, 19, 21) . Initial presentation with cardiac arrest was also a significant independent predictor of pre-treatment embolism. Severe LV dysfunction due to chronic myocardial infarction or symptomatic heart failure is a well-known risk factor for cerebral infarc-ical circulatory support (intra-aortic balloon pump or extracorporeal membrane oxygenation) and 2 of 8 patients (25%) had highly mobile or multiple thrombi which embolized preoperatively. Theoretically, complete resolution or treatment of thrombus will eliminate the possibility of systemic thromboembolism. Reports of operative treatment of LV thrombus have been scarce; most such reports are confined to case reports or case series. Previously Nili, M et al. reported 4 cases of surgical removal of LV thrombus; these patients did not develop post-treatment thromboembolism after thrombectomy with or without CABG, similar to our findings 22) . All other reports were case reports of successful removal of an LV thrombus through thrombectomy or video-assisted transaortic removal with excellent postoperative results [23] [24] [25] .
Bleeding Risk of Conventional Anticoagulation
Conventional anticoagulation is known to confer about a 20% risk of bleeding 6) ; the bleeding rate of our study was 11.9%, including 2 major bleeds, with 1 death due to bleeding. The most serious bleeding complication, intracranial hemorrhage, causes approximately 90% of deaths and most of the permanent disability in patients with warfarin-associated bleeding 26) . Anticoagulation with warfarin increases the risk Supplementary Table 4 . Propensity Score Matching between the Anticoagulation and Antiplatelet Agent Groups ＊ High-risk thrombus was defined as mobile or multiple left ventricular thrombi. ‡ Bleeding events were defined according to the Thrombolysis in Myocardial Infarction (TIMI) criteria. Major bleeding was defined as any intracranial hemorrhage, more than a 5 g/dL decrease in the hemoglobin concentration or more than a 15% absolute decrease in the hematocrit. Abbreviations: CVA, cerebrovascular accident; echo, echocardiography. Interval to follow-up echocardiography, data are expressed as the median and interquartile range. One patient with severe aortic stenosis with LV thrombus was treated with operative treatment (aortic valve replacement with LV thrombectomy). # One patient with stress-induced cardiomyopathy was treated only with antiplatelet agent. Abbreviations: CAD, coronary artery disease; CRF, chronic renal failure; IQR, interquartile range; LA, left atrium; LAVI, left atrium volume index; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; RWMA, regional wall motion abnormality; STEMI, ST segment elevation myocardial infarction. increased CYP3A4 activity. Warfarin undergoes extensive metabolism by the cytochrome P450 isoforms. CYP2C9 is responsible for the metabolism of S-warfarin, while R-warfarin is metabolized by CYP1A2, CYP2C19 and CYP3A4 37) . Enhanced activity of CYP3A4 in women would increase warfarin clearance compared to in men. Furthermore, differences in the hormonal status (menopause) could influence thrombogenicity. Taken together, differences in CYP enzyme activity and the hormonal status might affect the response to clopidogrel and warfarin use in women. Of note, sex differences in ischemic stroke or postoperative stroke after carotid endarterectomy were frequently described 38, 39) .
Supplementary
These aforementioned high-risk patients for posttreatment embolism need to be more aggressively treated and closely followed.
Limitations
Some important limitations of this study should be considered. First, this study was performed using a single center database with a relatively small number of patients, which might have lacked statistical power to detect differences in the primary outcome among treatment groups. Second, this study was a retrospective, descriptive study that could not control for unmeasured confounders. Even though we used propensity score matching and Cox proportional hazard regression modeling to minimize the influence of potential confounders, the possible influences of uncontrolled and unknown confounding factors should be considered. In addition, there were no data regarding the presence of thrombophilia, for example, protein C, S or antithrombin deficiency or antiphospholipid antibody syndrome, because thrombophilia evaluation is not routinely performed in our hospital. However, obesity and impaired renal function, which tion 31) . Myocardial dysfunction, including severe LV dysfunction or symptomatic heart failure, is a common manifestation in survivors of cardiac arrest 32) ; therefore, cardiac arrest might be the precipitating cause of embolic cerebral infarction.
Since pre-treatment embolism is difficult to prevent, it is more important to indentify predictors of post-treatment embolism. In this study, a prior cerebrovascular accident, idiopathic DCMP and large LVEDD were found to be independent predictors of post-treatment embolism. Recently, Sharma et al. reported that LVEDD was significantly associated with the development of LV thrombus but not with systemic thromboembolism, and predictors of systemic thromboembolism were ischemic cardiomyopathy and low EF 4) . In contrast, in the current study, idiopathic DCMP (but not ischemic cardiomyopathy) was the most powerful predictor of systemic thromboembolism. However, DCMP and a previous history of cerebral infarction or transient ischemic attack are already known to be strong risk factors for cardiogenic embolism and cerebral infarction 33) . All patients with DCMP were treated with anticoagulation; this uneven distribution of treatment modality could be one of the reasons that DCMP was found to be an independent predictor; however, DCMP remained an independent predictor of post-treatment thromboembolism after adjusting for the treatment modality and underlying heart condition.
Interestingly, female gender was also an independent predictor of post-treatment thromboembolism. In the literature, there is no clear explanation of why female gender was associated with increased thromboembolic risk. Recently, female gender was reported to be associated with an increased risk for clopidogrel hypo-responsiveness 34, 35) . Gender-specific differences exist in the activity of CYP enzymes 36) . Men have increased CYP1A2 activity, while women have rence of LV thrombus. Fourth, the uneven distribution of the patients among the treatment groups and possible allocation bias should be considered. All patients with dilated cardiomyopathy were treated with anticoagulation; hence, this study could not compare treatment modalities for this subgroup. All are also associated with enhanced thrombogenesis 40, 41) , were evaluated as independent predictors of posttreatment thromboembolism; we did not find a notable association with post-treatment thromboembolism. Third, the limited sensitivity of TTE for the detection of LV thrombus may have underestimated the recur-Supplementary Abbreviations: AS, aortic stenosis; CAD, coronary artery disease; CMP, cardiomyopathy; CRF, chronic renal failure; CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; HCMP, hypertrophic cardiomyopathy; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LVEF, left ventricular ejection fraction; RWMA, regional wall motion abnormality. patients in the operative treatment group had another absolute indication for open heart surgery, i.e. 3-vessel disease requiring CABG or severe aortic stenosis requiring aortic valve replacement. While the operative treatment group had the potential for improvement of their left ventricular function, most of the patients in the conventional anticoagulation group had low potential for improvement of their left ventricular function.
All statements about the possible superiority of operative treatment should be taken as hypothesis generating. In fact, it is difficult to recommend openheart surgery to patients whose only indication is LV thrombus; however, our study reflects the current management of LV thrombus. Nonetheless, in patients with a high-risk profile, surgical removal might reduce the incidence of thromboembolism more than anticoagulation therapy. It is unknown whether the reduction in post-treatment thromboembolism outweighs the risk of surgery related morbidity and mortality. Nevertheless, to the best of our knowledge, the current study is the first report to compare the long-term efficacy and consequences of anticoagulation, operative treatment, and antiplatelet agents for the treatment of LV thrombus. We expect that these limitations will be more appropriately addressed in future randomized trials comparing anticoagulation with operative treatment in patients with LV thrombus.
Conclusion
The rate of post-treatment thromboembolism did not differ significantly among the three treatment groups. Nonetheless, we observed a tendency towards a lower rate of post-treatment embolism in the operative treatment group. Given the risk of bleeding and insufficient resolution rate with anticoagulation, alternative or additive treatment, especially for patients at high risk for systemic thromboembolism should be considered. Further prospective randomized controlled studies are needed to clarify these issues.
